Barely Significant
← all excerpts

Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.

Int J Mol Sci · 2025 · PMC12027891 · PMID 40332761

Europe PMCDOI
1
hedged sentence
0.0520
closest p · 1.0× alpha
0.0520
boldest claim

The sentences

showed a trendp = 0.052so close (0.05 < p ≤ 0.1)
A recent phase II trial for patients with residual disease or high-risk pCR after receiving neoadjuvant or postoperative anti-HER2 agents reported that the GP2 vaccine had no significant benefit in DFS in the total population, yet a subset analysis showed a trend toward improved DFS in the HER2+ group that received the GP2 vaccine ( p = 0.052) [ 46 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.